ATHOS, a Munich based single family office, led a €30m Series A round in Bactolife, a bioindustrial company, with participation from Bill & Melinda Gates Foundation, and Novo Holdings. “We are very pleased and humbled by the continued confidence that investors have shown us, especially in times of geopolitical uncertainty and market turmoil. The funding allows us to increase our investments in our project pipeline, technology platform, organisation and upscaling capabilities. Further, it will enable Bactolife to accelerate our partnering efforts with world-leading companies and commercialise our first product concepts for humans and animals,” Sebastian Søderberg, Bactolife CEO.